GH

Over the past six months, Guardant Health's stock has experienced several notable events. In January 2026, the company announced preliminary unaudited results for Q4 and full year 2025, reporting revenue increases. In February 2026, Guardant Health reported Q4 2025 earnings, missing EPS estimates but beating revenue expectations. In April 2026, the stock slid after FDA briefing documents raised concerns about AstraZeneca's SERENA-6 trial, Guardant Health announced a collaboration with Nuvalent, and the company disclosed the resignation of Chief Medical Officer Craig Eagle. In May 2026, Guardant Health surged after receiving FDA approval for Guardant360 CDx, reported Q1 2026 financial results with revenue increasing, and raised its full-year 2026 revenue guidance. Guardant Health's stock price has ranged between a low of $36.36 and a high of $120.74 over the past 52 weeks.